Research Analysts Issue Forecasts for AURA Q1 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Aura Biosciences in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.47) EPS and Q4 2025 earnings at ($0.51) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02.

AURA has been the topic of several other research reports. BTIG Research boosted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Finally, Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Aura Biosciences currently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $8.01 on Friday. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The company’s 50-day moving average is $8.22 and its 200 day moving average is $8.88. The stock has a market capitalization of $400.10 million, a P/E ratio of -4.63 and a beta of 0.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. Charles Schwab Investment Management Inc. increased its holdings in Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after buying an additional 3,612 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after buying an additional 8,194 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Aura Biosciences during the fourth quarter valued at approximately $87,000. Renaissance Technologies LLC increased its holdings in Aura Biosciences by 26.3% during the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after buying an additional 15,000 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Aura Biosciences during the third quarter valued at approximately $169,000. Institutional investors own 96.75% of the company’s stock.

Insider Transactions at Aura Biosciences

In related news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now owns 151,693 shares in the company, valued at $1,419,846.48. This represents a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,778 shares of company stock worth $240,706. Corporate insiders own 5.40% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.